Attached files

file filename
EX-3.1 - CERTIFICATE OF AMENDMENT OF AMENDED AND RESTATED CERTIFICATE - CADENCE PHARMACEUTICALS INCd367795dex31.htm

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 13, 2012

 

 

Cadence Pharmaceuticals, Inc.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   001-33103   41-2142317

(State or other jurisdiction

of incorporation)

 

(Commission

File Number)

 

(IRS Employer

Identification No.)

12481 High Bluff Drive, Suite 200

San Diego, California 92130

(Address of principal executive offices, including zip code)

(858) 436-1400

(Registrant’s telephone number, including area code)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 


Item 5.03. Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.

At the Annual Meeting of Stockholders held on June 13, 2012, the stockholders of Cadence Pharmaceuticals, Inc. (the “Company”) approved an amendment to the Company’s Amended and Restated Certificate of Incorporation to increase the authorized number of shares of common stock from 100,000,000 to 200,000,000. Following the meeting, the Company filed a Certificate of Amendment of Amended and Restated Certificate of Incorporation with the Secretary of State of the State of Delaware, which became effective on June 13, 2012.

The foregoing description does not purport to be complete and is qualified in its entirety by reference to the complete text of the Certificate of Amendment of Amended and Restated Certificate of Incorporation, which is filed as Exhibit 3.1 to this report and is incorporated herein by reference.

 

Item 5.07. Submission of Matters to a Vote of Security Holders.

On June 13, 2012, the Company held its Annual Meeting of Stockholders in San Diego, California, at which the stockholders voted on proposals as follows:

Proposal 1. The election of Mr. Cam L. Garner, Mr. Brian G. Atwood, Dr. Samuel L. Barker and Mr. Michael L. Eagle as directors for a three-year term expiring at the 2015 Annual Meeting of Stockholders:

 

Nominee

  

For

  

Withheld

  

Broker Non-Votes

Cam L. Garner

   58,307,617    15,966,935    7,887,306

Brian G. Atwood

   61,769,871    12,504,681    7,887,306

Samuel L. Barker

   59,575,420    14,699,132    7,887,306

Michael L. Eagle

   62,202,736    12,071,816    7,887,306

Proposal 2. The approval of an amendment to the Company’s Amended and Restated Certificate of Incorporation to increase the authorized number of shares of common stock from 100,000,000 to 200,000,000:

 

For

  

Against

  

Abstain

  

Broker Non-Votes

77,767,710

   4,392,480    1,668    N/A

Proposal 3. The ratification of the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2012:

 

For

  

Against

  

Abstain

  

Broker Non-Votes

81,982,407

   71,782    107,669    N/A

 

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

 

Exhibit

Number

  

Description of Exhibit

3.1    Certificate of Amendment of Amended and Restated Certificate of Incorporation of the Company, dated June 13, 2012


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

CADENCE PHARMACEUTICALS, INC.
By:  

/s/ William R. LaRue

  William R. LaRue
  Senior Vice President, Chief Financial Officer, Treasurer and Assistant Secretary

Date: June 15, 2012


EXHIBIT INDEX

 

Exhibit
Number

  

Description of Exhibit

3.1    Certificate of Amendment of Amended and Restated Certificate of Incorporation of the Company, dated June 13, 2012